Results 91 to 100 of about 1,164,667 (298)

A High-Quality Melon Genome Assembly Provides Insights into Genetic Basis of Fruit Trait Improvement

iScience, 2019
Summary: Accurate reference genomes have become indispensable tools for characterization of genetic and functional variations. Here we generated a high-quality assembly of the melon Payzawat using a combination of short-read sequencing, single-molecule ...
Hong Zhang, Xuming Li, Haiyan Yu, Yongbing Zhang, Meihua Li, Haojie Wang, Dengming Wang, Huaisong Wang, Qiushi Fu, Min Liu, Changmian Ji, Liming Ma, Juan Tang, Song Li, Jianshun Miao, Hongkun Zheng, Hongping Yi   +16 more
doaj   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Mining nucleic acid “omics” to boost liquid biopsy in cancer

Cell Reports Medicine
Summary: Treatments for cancer patients are becoming increasingly complex, and there is a growing desire from clinicians and patients for biomarkers that can account for this complexity to support informed decisions about clinical care.
Ann Tivey, Rebecca J. Lee, Alexandra Clipson, Steven M. Hill, Paul Lorigan, Dominic G. Rothwell, Caroline Dive, Florent Mouliere   +7 more
doaj   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Methodologies for the Emulation of Biomarker-Guided Trials Using Observational Data: A Systematic Review [PDF]

Background: Target trial emulation involves the application of design principles from randomised controlled trials (RCTs) to observational data, and is particularly useful in situations where an RCT would be unfeasible.
Khalaf, RKS, Faye D. Baldwin, Andrea L. Jorgensen, Ruwanthi Kolamunnage-Dona, Baldwin, FD, Kolamunnage-Dona, R, Jorgensen, AL, Rukun K. S. Khalaf   +7 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Micronucleus quantification from whole-slide haematology images using AI serves as a translatable pharmacodynamic biomarker for DNA damage response inhibitors

Scientific Reports
Micronuclei are widely recognised biomarkers of genomic instability and DNA damage, making their accurate quantification essential for understanding the pharmacodynamic properties of chemotherapeutic agents and inhibitors of the DNA damage response (DDR).
Killian H. R. Yong, Weronika S. Robak, Lee Mulderrig, Adina Hughes, Richard Bystry, Tanya Wantenaar, Gemma N. Jones, Maria Udriste, Jack Robertson, Josep V. Forment, Lenka Oplustil O’Connor, Ross J. Hill   +11 more
doaj   +1 more source

Global Biomarker Implementation in the WHO’s World Health Survey Plus [PDF]

, 2023
Single page posterThe Global Health Biomarker Laboratory is collaborating with the World Health Organization to plan and implement the World Health Survey Plus (WHS+).
Getz, Madeleine, Warner-Carey, Micah, Taylor, Rosa   +2 more
core  

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Latest developments in advanced exosome engineering for optimized site-specific drug delivery by modulating exosome functionalities in breast cancer

Discover Pharmaceutical Sciences
Breast cancer (BC), the second most common cancer worldwide, is frequently treated with chemotherapeutic agents as part of neoadjuvant therapies. However, the major drawback of chemotherapy comes at the cost of nonspecific drug targets.
Bikram Dawn, Api Talom, Taba Jirpu, Arnab Ghosh   +3 more
doaj   +1 more source